p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression

American Journal of Gastroenterology

Volumn 96, Issue 5, 2001, Pages 1355-1362

  Weston, Allan P ^b,c   Banerjee, Sushanta K ^a,b   Sharma, Prateek ^b,c   Tran, Trang M ^a,b   Richards, Robert ^b,c   Cherian, Rachel ^b,c  

^a Research Division   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DYSPHAGIA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SECONDARY PREVENTION; TUMOR SUPPRESSOR GENE;

EID: 0035007905     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02414-5     Document Type: Article

References (50)

1. Haggitt R.C. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 25:1994;982-993.
2. Haggitt R.C., Reid B.J., Rabinovitch P.S., Rubin C.E. Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am J Pathol. 131:1988;53-61.
3. Levine D.S. Barrett's oesophagus and p53. Lancet. 344:((8917)):1994;212-213.
4. Neshat K., Sanchez C.A., Galipeau P.C., et al. Barrett's esophagus A model of human neoplastic progression . Cold Spring Harb Symp Quant Biol. 59:1994;577-583.
5. Sampliner R.E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 93:1998;1028-1032.
6. Garewal H., Ramsey L., Sharma P., et al. Biomarker studies in reversed Barrett's esophagus. Am J Gastroenterol. 94:1999;2829-2833.
7. Reid B.J. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. 20:1991;817-834.
8. Reid B.J., Blount P.L., Rubin C.E., et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus Prospective endoscopic surveillance of a cohort . Gastroenterology. 102:1992;1212-1219.
9. Blount P.L., Rabinovitch P.S., Reid B.J. DNA content flow cytometry and neoplastic progression in the gastrointestinal tract. Eastwood G.L. Premalignant conditions of the gastrointestinal tract. Pathogenesis, diagnosis, and management. 1990;55-77 Elsevier, New York.
10. Weston A.P., Krmpotich P.T., Cherian R., et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus Comparison with traditional long segment Barrett's esophagus . Am J Gastroenterol. 92:1997;407-413.
11. Weston A.P., Krmpotich P.T., Cherian R., et al. Prospective evaluation of intestinal metaplasia and dysplasia within the cardia of patients with Barrett's esophagus. Dig Dis Sci. 42:1997;597-602.
12. Weston A.P., Badr A.S., Hassanein R.S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol. 94:1999;3413-3419.
13. Reid B.J., Haggitt R.C., Rubin C.E., et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 19:1988;166-178.
14. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:((5015)):1991;49-53.
15. Kastan M.B., Onyekwere O., Sidransky D., et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
16. Culotta E., Koshland D.E. Jr. p53 sweeps through cancer research. Science. 262:((5142)):1993;1958-1961.
17. McKay B.C., Ljungman M., Rainbow A.J. Potential roles for p53 in nucleotide excision repair. Carcinogenesis. 20:1999;1389-1396.
18. Arrowsmith C.H. Structure and function in the p53 family. Cell Death Differ. 6:1999;1169-1173.
19. Lohrum M.A., Vousden K.H. Regulation and activation of p53 and its family members. Cell Death Differ. 6:1999;1162-1168.
20. Ikawa S., Nakagawara A., Ikawa Y. p53 family genes Structural comparison, expression and mutation . Cell Death Differ. 6:1999;1154-1161.
21. el Deiry W.S., Harper J.W., O'Connor P.M., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
22. Krishnadath K.K., Tilanus H.W., van Blankenstein M., et al. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol. 175:1995;175-180.
23. Gimenez A., Minguela A., Parrilla P., et al. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus. Cancer. 83:1998;641-651.
24. Ramel S., Reid B.J., Sanchez C.A., et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology. 102:1992;1220-1228.
25. Jones D.R., Davidson A.G., Summers C.L., et al. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg. 57:1994;598-603.
26. Rice T.W., Goldblum J.R., Falk G.W., et al. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. J Thorac Cardiovasc Surg. 108:1994;1132-1137.
27. Hanas J.S., Lerner M.R., Lightfoot S.A., et al. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus. Cancer. 86:1999;756-763.
28. Polkowski W., van Lanschot J.J., Ten Kate F.J., et al. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol. 4:1995;163-171.
29. Ireland A.P., Clark G.W., DeMeester T.R. Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg. 225:1997;17-30.
30. Kubba A.K., Poole N.A., Watson A. Role of p53 assessment in management of Barrett's esophagus. Dig Dis Sci. 44:1999;659-667.
31. Fitzgerald R.C., Triadafilopoulos G. Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis. 16:1998;63-80.
32. Levine D.S. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin North Am. 26:1997;613-634.
33. Rabinovitch P.S., Reid B.J., Haggitt R.C., et al. Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest. 60:1989;65-71.
34. Reid B.J., Rabinovitch P.S. Barrett's esophagus. A human model of genomic instability in neoplastic progression. Hirschowitz B.I. Accomplishments in oncology. Vol. 3:1989;32-44 Lippincott, Philadelphia.
35. Weston A.P., Sharma P., Topalovski M., et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol. 95:2000;1887-1893.
36. Nigro J.J., Hagen J.A., DeMeester T.R., et al. Occult esophageal adenocarcinoma. Extent of disease and implications for effective therapy. Ann Surg. 230:1999;433-440.
37. Schmidt H.G., Riddell R.H., Walther B., et al. Dysplasia in Barrett's esophagus. J Cancer Res Clin Oncol. 110:1985;145-152.
38. Riddell R.H., Goldman H., Ransohoff D.F., et al. Dysplasia in inflammatory bowel disease standardized classification with provisional clinical applications . Hum Pathol. 14:1983;931-968.
39. Bronner M.P. Columnar lined epithelium and dysplasia - confirming the diagnosis. Presented at Esophagology for Clinicians: Pathophysiology, Diagnosis & Therapy; December 2-4, 1999; Orlando.
40. Zoubine M.N., Weston A.P., Johnson D.C., et al. 2-Methoxyestradiol-induced growth suppression and lethality in estrogen-responsive MCF-7 cells may be mediated by down regulation of p34cdc2 and cyclin B1 expression. Int J Oncol. 15:1999;639-646.
41. Banerjee S.K., Weston A.P., Zoubine M.N., et al. Expression of cdc2 and cyclin B1 in helicobacter pylori-associated gastric MALT and MALT lymphoma Relationship to cell death, proliferation, and transformation . Am J Pathol. 156:2000;217-225.
42. Menke-Pluymers M.B., Mulder A.H., Hop W.C., et al. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut. 35:1994;1348-1351.
43. Miros M., Kerlin P., Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut. 32:1991;1441-1446.
44. Younes M., Ertan A., Lechago L.V., et al. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci. 42:1997;697-701.
45. Krishnadath K.K., van Blankenstein M., Tilanus H.W. Prognostic value of p53 in Barrett's oesophagus. Eur J Gastroenterol Hepatol. 7:1995;81-84.
46. Hamelin R., Flejou J.F., Muzeau F., et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology. 107:1994;1012-1018.
47. Muzeau F., Flejou J.F., Potet F., et al. Profile of p53 mutations and abnormal expression of p53 protein in 2 forms of esophageal cancer. Gastroenterol Clin Biol. 20:1996;430-437. (in French).
48. Iftikhar S.Y., James P.D., Steele R.J., et al. Length of Barrett's oesophagus An important factor in the development of dysplasia and adenocarcinoma . Gut. 33:1992;1155-1158.
49. O'Connor J.B., Falk G.W., Richter J.E. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus Report on the Cleveland Clinic Barrett's Esophagus Registry . Am J Gastroenterol. 94:1999;2037-2042.
50. Alikhan M., Rex D., Khan A., et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Am J Gastroenterol. 50:1999;23-26.